文献速递血脂与心血管预防

Inclisiran在家族性高胆固醇血症或动脉粥样硬化患者中的汇总患者水平分析

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

该研究对3项3期试验(ORION-9、-10、-11)进行患者水平汇总分析,共纳入3660例接受最大耐受剂量他汀治疗(±其他降脂药)的杂合子家族性高胆固醇血症、ASCVD或ASCVD风险等同患者,随机接受inclisiran或安慰剂皮下注射(第1天、第90天,之后每6个月一次,共540天)。结果显示,inclisiran组第510天LDL-C安慰剂校正变化为-50.7%(95%CI:-52.9%至-48.4%;p<0.0001),安全性总体与安慰剂相似,注射部位不良事件更常见但多为轻度。

要点

  • inclisiran每年两次皮下注射,在最大耐受他汀基础上进一步降低LDL-C约50%。
  • 注射部位不良事件发生率5.0% vs 0.7%,但多为轻度,无严重或持续性事件。
  • 肝肾功能、肌酸激酶和血小板计数在两组间无差异。

核心结论

  • 在杂合子家族性高胆固醇血症、ASCVD或ASCVD风险等同成人中,inclisiran每年两次给药联合最大耐受他汀治疗(±其他降脂药)可有效、安全且耐受良好地降低LDL-C。

研究设计与样本

  • 对3项3期试验(ORION-9、ORION-10、ORION-11)进行患者水平汇总分析,共3660例受试者随机(ORION-9 n=482,ORION-10 n=1561,ORION-11 n=1617)。
  • 受试者按1:1随机接受inclisiran或安慰剂皮下注射,第1天、第90天给药,之后每6个月一次,持续540天。
  • 共同主要终点为第510天LDL-C相对基线安慰剂校正百分比变化,以及第90天后至第540天LDL-C相对基线时间校正百分比变化。

主要发现

  • inclisiran组第510天LDL-C安慰剂校正变化为-50.7%(95%CI:-52.9%至-48.4%;p<0.0001)。
  • inclisiran组第90天后至第540天LDL-C时间校正安慰剂校正变化为-50.5%(95%CI:-52.1%至-48.9%;p<0.0001)。
  • 注射部位治疗中出现的不良事件在inclisiran组更常见(5.0% vs 0.7%),但主要为轻度,无严重或持续性事件。
  • 肝肾功能检查、肌酸激酶值和血小板计数在两组间无差异。

关键数值与推荐

  • LDL-C疗效评估:第510天安慰剂校正百分比变化-50.7%(95%CI:-52.9%至-48.4%;p<0.0001)。
  • LDL-C疗效评估:第90天后至第540天时间校正安慰剂校正百分比变化-50.5%(95%CI:-52.1%至-48.9%;p<0.0001)。
  • 安全性:注射部位治疗中出现的不良事件发生率inclisiran组5.0%,安慰剂组0.7%。

临床怎么用

  • 对于接受最大耐受他汀治疗(±其他降脂药)的杂合子家族性高胆固醇血症、ASCVD或ASCVD风险等同患者,可考虑每年两次inclisiran皮下注射以进一步降低LDL-C。
  • 用药期间应关注注射部位反应,但多数为轻度,无需特殊处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inclisiran is a double-stranded small interfering RNA that suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) translation in the liver, leading to sustained reductions in low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins with twice-yearly dosing. OBJECTIVES: The purpose of this study was to conduct a patient-level pooled analysis from 3 phase 3 studies of inclisiran. METHODS: Participants with heterozygous familial hypercholesterolemia (ORION-9 [Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)]), atherosclerotic cardiovascular disease (ASCVD) (ORION-10 [Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol]), or ASCVD and ASCVD risk equivalents (ORION-11 [Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol]) taking maximally tolerated statin therapy, with or without other LDL-C-lowering agents, were randomly assigned in a 1:1 ratio to receive either inclisiran or placebo, administered by subcutaneous injection on day 1, day 90, and every 6 months thereafter for 540 days. The coprimary endpoints were the placebo-corrected percentage change in LDL-C level from baseline to day 510 and the time-adjusted percentage change in LDL-C level from baseline after day 90 to day 540. Levels of other atherogenic lipoproteins and treatment-emergent adverse events were also assessed. RESULTS: A total of 3,660 participants (n = 482, n = 1,561, and n = 1,617 from ORION-9, -10, and -11, respectively) underwent randomization. The placebo-corrected change in LDL-C with inclisiran at day 510 was -50.7% (95% confidence interval: -52.9% to -48.4%; p < 0.0001). The corresponding time-adjusted change in LDL-C was -50.5% (95% confidence interval: -52.1% to -48.9%; p < 0.0001). Safety was similar in both groups. Treatment-emergent adverse events at the injection site were more frequent with inclisiran than placebo (5.0% vs. 0.7%), but were predominantly mild, and none were severe or persistent. Liver and kidney function tests, creatine kinase values, and platelet counts did not differ between groups. CONCLUSIONS: These pooled safety and efficacy data show that inclisiran, given twice yearly in addition to maximally tolerated statin therapy with or without other LDL-C lowering agents, is an effective, safe, and well-tolerated treatment to lower LDL-C in adults with heterozygous familial hypercholesterolemia, ASCVD, or ASCVD risk equivalents.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Wright RS, Ray KK, Raal FJ, et al. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021. PMID: 33663735. doi:10.1016/j.jacc.2020.12.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。